Engineered biomaterials for heart disease

Lyndsay Stapleton; Yuanjia Zhu; Yi-Ping Joseph Woo; Eric Appel

doi:10.1016/j.copbio.2020.08.008

Engineered biomaterials for heart disease

Curr Opin Biotechnol. 2020 Dec:66:246-254. doi: 10.1016/j.copbio.2020.08.008. Epub 2020 Oct 1.

Authors

Lyndsay Stapleton¹, Yuanjia Zhu², Yi-Ping Joseph Woo³, Eric Appel⁴

Affiliations

¹ Department of Bioengineering, Stanford University, Stanford, CA 94305, USA; Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, USA; Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305, USA.
² Department of Bioengineering, Stanford University, Stanford, CA 94305, USA; Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, USA.
³ Department of Bioengineering, Stanford University, Stanford, CA 94305, USA; Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, USA. Electronic address: joswoo@stanford.edu.
⁴ Department of Bioengineering, Stanford University, Stanford, CA 94305, USA; Department of Materials Science & Engineering, Stanford University, Stanford, CA 94305, USA. Electronic address: eappel@stanford.edu.

Abstract

Ischemic heart disease is the most common type of heart disease, responsible for roughly 10 million deaths worldwide annually. While standard clinical interventions have resulted in improved patient outcomes, access to small diameter vessels required for cardiovascular interventions, and long-term patient mortality rates associated with eventual heart failure, remain critical challenges. In this current opinion piece we discuss novel methodologies for the advancement of vascular grafts, cardiac patches, and injectable drug delivery depot technologies as they relate to treatment of ischemic heart disease, including bilayered conduits, acellular bioactive extracellular matrix (ECM) scaffolds, and protease-responsive hydrogel delivery platforms. We address the motivation for innovation and current limitations in the field of engineered biomaterials for myocardial ischemia therapeutics and interventions.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Biocompatible Materials*
Extracellular Matrix
Heart Diseases* / surgery
Humans
Hydrogels
Tissue Engineering
Tissue Scaffolds

Substances

Biocompatible Materials
Hydrogels

Grants and funding

R01 HL089315/HL/NHLBI NIH HHS/United States